Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
#PharmaNews #PharmaResults #EarningsUpdate #IndianPharma #PharmaUpdates #Harshal #PharmawithHJ #HJ Gland Pharma FY25 Results: Strong Margins, 31 Product Launches Gland Pharma Limited FY25 Results: Margins Hold Strong, Strategy Gathers Steam Financial Highlights: - FY25 Revenue: 5,617 Cr (1% YoY) - EBITDA Margin: 1,269 Cr (5% YoY) | Margin 23% - PAT: 698 Cr (10% YoY) | Margin at 12% - Dividend: 18/share final dividend recommended Business Highlights: - 31 product launches in FY25, including new molecules like Latanoprost & Dexamethasone - 32 ANDA approvals, 24 filings U.S
These data prompted us to examine the immunity phenotype of the three sterile mutants
Periodic touch-up sessions yearly can help to manage regrowth
54 The main drawback to IV therapy with glutathione is that it requires clinic visits, whereas glutathione injections can be administered at home if your doctor prescribes them
US$ 20.74
US$ 23.82
US$ 22.87
US$ 24.09
US$ 28.23
US$ 21.33
US$ 24.68
US$ 20.86
